Search Results for: mscs

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD

Cynata

Cynata Therapeutics Limited has received approval from UK regulators to start a first-of-its-kind allogeneic IPSC-based trial of MSCs for graft versus host disease (GVHD). Cynata also had some big news a couple weeks back with a deal with Fujifilm. The company is aiming to recruit 16 patients to test whether the MSCs (a type of adult …

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD Read More »

Interview with Bob Lanza on new ACT MSCs for MS paper

I did a brief email Q&A interview with Dr. Bob Lanza of Advanced Cell Technology (ACT) on their new hES MSCs pre-clinical data for Multiple Sclerosis. I discussed the paper itself in a concise review yesterday here. Thanks to Dr. Lanza for doing the interview. 1. Were you surprised at the fact that the therapeutic …

Interview with Bob Lanza on new ACT MSCs for MS paper Read More »

Review of New ACT Paper on hESC-derived MSCs

advanced-cell-technology-150x1501

Advanced Cell Technology (ACT; $ACTC) has a new paper out on using human embryonic stem cells (hESC) to make MSCs with potentially powerful therapeutic potential. The paper, entitled Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties, was published in the journal Stem Cells and Development. What’s the scoop on this …

Review of New ACT Paper on hESC-derived MSCs Read More »

ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis

dancing-mice

Is Advanced Cell Technology (ACT) on the road to cure Multiple Sclerosis (MS) using stem cells and specifically MSCs? Some folks seem to think it’s quite possible, but I remain skeptical. Still there have been some interesting developments. ACT has a relatively new patent filing for a mesenchymal stromal cell (MSC) product that was just …

ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis Read More »

Interview with Arnold Caplan, Part 3: challenges & opportunities for clinical use of MSCs

I recently had a phone interview with Dr. Arnold Caplan, the founder of the MSC field. You can read parts 1 and 2 of the interview here and here. Today’s post, part 3, is focused on clinical use of MSCs. I want to start off today’s post with a wonderful quote from Caplan: “All MSCs …

Interview with Arnold Caplan, Part 3: challenges & opportunities for clinical use of MSCs Read More »

Weekly reads: Xist & autoimmune disease in women, Crohn’s disease, dumb headline of the week

Xist ,auto immune disease

Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years. …

Weekly reads: Xist & autoimmune disease in women, Crohn’s disease, dumb headline of the week Read More »

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

CRISPR Therapeutics

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and …

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

Surprising new FDA remarks to AABB on cord biologics misuse & stem cell clinics

AABB, FDA

The Association for the Advancement of Blood & Biotherapies or AABB recently had a very useful Q&A with the FDA on cord blood use. There are some important new things from the FDA on the marketing and use of cord blood in there. The agency was also quite blunt in some ways about the challenges, …

Surprising new FDA remarks to AABB on cord biologics misuse & stem cell clinics Read More »

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell

Athersys stock, Athersys, stem cell stocks

I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over …

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell Read More »

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up?

Burst Biologics, Christopher Jones

The New York Times just broke a story on Burst Biologics and Weill Cornell that fits with long-standing troubling questions about regenerative biologics producers. The story also bears on the doctors and hospitals like Weill Cornell that were or are customers of the suppliers. Further, what is the FDA’s role in all of this? The …

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up? Read More »